Anger over cancer drug decisionPress AssociationUpdated 14 July 2016 at 9:32 pmPharmaceuticalsA life-extending drug hailed as a breakthrough for prostate cancer sufferers is too expensive to be used on the NHS, watchdogs have ruled.Cabazitaxel, which is marketed as Jevtana, can extend the life of late-stage patients by an average of three months.
Anger over cancer drug decisionPress AssociationUpdated 14 July 2016 at 9:32 pmPharmaceuticalsA life-extending drug hailed as a breakthrough for prostate cancer sufferers is too expensive to be used on the NHS, watchdogs have ruled.Cabazitaxel, which is marketed as Jevtana, can extend the life of late-stage patients by an average of three months.